BACKGROUNDː Deep venous system diseases remained out of the scope of vascular surgeons’ interest for decades except for conservative
therapy. Regarding venous thromboembolism (Vte), anticoagulants were and still the primary therapy in spite of documented thrombus related
long-term sequalae. Percutaneous thrombus removal becomes the first therapeutic option for lower extremity extensive DVT when not contrain-
dicated. The goal of our study was to evaluate the outcome of patients treated with AngioJet pharmacomechanical thrombectomy (APMT) and
Aspirex mechanical thrombectomy (AMT) catheter vs. pharmacological catheter directed lysis (CDT) alone.
METHODS: We analyzed 49 patients retrospectively with extensive lower extremity DVT treated with thrombus removal techniques as first
therapeutic option from January 2016 to December 2019. Our measured outcomes were successful regaining vessel patency, lytic drug dose and
exposure time evaluation and the incidence of complications as a primary endpoint. While the incidence of post-thrombotic syndrome (PTS) was
the secondary endpoint at 24 months follow-up.
RESULTSː Successful regaining patency was 100% in group I (APMT), 95.8% in group II (CDT) and 90.9% in group III (AMT). There was
a significant reduction in lytic drug dose, procedure time, ICU admission and total hospital stay in both group I and III compared to group II
(P |
